Falbikitug clinical trials
Also written AZD0171 and MSC-1.
How each study uses falbikitug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the falbikitug studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Oleclumab (1) · Monalizumab (1) · Datopotamab deruxtecan (1) · Carboplatin (1) · Cisplatin (1) · Pemetrexed (1) · Carboplatin/Paclitaxel Regimen (1) · Volrustomig (1)
Studies
Open first, then newest update. How each study uses falbikitug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingPhase 2AstraZenecaNCT05061550Written as AZD0171
- Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid TumoursActive, not recruitingPhase 2AstraZenecaNCT04999969Written as AZD0171
- Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid TumorsCompletedPhase 1AstraZenecaNCT03490669Written as MSC-1
Codes
What other systems call falbikitug · ClinicalTrials.gg INT016413
- UNII (FDA) E4JL3K3CI6FALBIKITUGOne source FDA
- NCI Thesaurus C156176FalbikitugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | E4JL3K3CI6 | FALBIKITUG | One source FDA |
| NCI Thesaurus | C156176 | Falbikitug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.